Targovax's Series A - II Round

Targovax raised a round of funding on June 06, 2013.

Targovax is an Oslo-area based global biotechnology company, dedicated to the design and development of immunotherapy vaccines for patients with RAS-mutated cancers.…

Articles about Targovax's Series A - II Round: